Developer docs
API playgroundTry for free, no card

Search company profiles

Regranion

Full company profile

uuid003ein8

Namestring
Regranion
Legal namestring
Regranion, LLC
Websiteurl
regranion.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Regranion, LLC is a clinical-stage biopharmaceutical company developing RGRN-305, an orally delivered small molecule inhibitor of heat shock protein 90 (HSP90), for the treatment of autoimmune skin diseases. Founded in 2009 and headquartered in Mount Pleasant, United States, the company operates with a small team of 1-10 employees and is pre-revenue. Its lead asset targets hyperinflammation in moderate to severe plaque psoriasis and hidradenitis suppurativa (HS), with a mechanism of action designed to downregulate multiple inflammatory mediators simultaneously rather than inhibiting a single cytokine or chemokine.

RGRN-305 has demonstrated clinical safety and efficacy in both psoriasis and hidradenitis suppurativa trials, with no specific organ toxicity concerns and no consistent changes in hematology or biochemistry parameters reported in the available data. The product's pharmacological differentiation rests on broad-spectrum anti-inflammatory activity through HSP90 inhibition, an approach positioned by the company as addressing unmet clinical need in moderate to severe disease where single-target biologics have limitations.

The business model is a traditional pharmaceutical product sales model contingent on regulatory approval. The anticipated go-to-market is enterprise field sales targeting dermatologists, hospital systems, and specialty pharmacy channels, with distribution expected to flow through standard pharmaceutical wholesalers and specialty pharmacy networks upon commercialization. No pricing, partnerships, or capital structure details are disclosed in the source material.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMount Pleasant, United States
HQ citystring
Mount Pleasant
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
autoimmune skin diseases, HSP90 inhibitor, clinical-stage biopharmaceutical, small molecule therapeutics, anti-inflammatory drugs
Industry1 code
PRIMARYHLAKACAH
Acne & Rosacea Specialty Care
Product category
Dermatology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Revenue expected upon regulatory approval and commercialization of RGRN-305 for psoriasis and hidradenitis suppurativa. Revenue model would be traditional pharmaceutical product sales through prescription channels.

regranion.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Regranion is a clinical-stage biopharmaceutical company developing RGRN-305, an orally delivered small molecule inhibitor of heat shock protein 90 (HSP90) for the treatment of autoimmune skin diseases. The lead product targets hyperinflammation in moderate to severe plaque psoriasis and hidradenitis suppurativa through broad-spectrum anti-inflammatory activity, modulating multiple inflammatory mediators simultaneously rather than individual cytokines or chemokines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • No specific organ toxicity concerns and no consistent changes in hematology or biochemistry parameters in clinical trials
+1 more record
Product overview1 text field

Regranion is a clinical-stage biopharmaceutical company with a single lead product, RGRN-305. RGRN-305 is an orally delivered potent small molecule HSP90 inhibitor that functions as a broad-spectrum anti-inflammatory molecule, targeting multiple inflammatory mediators of autoimmune skin diseases rather than individual cytokines or chemokines. The product is in clinical development for hidradenitis suppurativa and plaque psoriasis, demonstrating clinical safety and efficacy without specific organ toxicity concerns.

Product and service1 record
1RGRN-305
CategoryLead product
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeBroad incumbent
Description

Dermatology-focused specialty pharma with products spanning acne, rosacea, and other inflammatory skin conditions. Indirectly comparable as a dermatology-specialized competitor with overlapping physician channels.

2Bristol-Myers Squibb
TypeBroad incumbent
Description

Markets Sotyktu (deucravacitinib), a first-in-class oral TYK2 inhibitor for psoriasis. Highly relevant comparator as the leading oral systemic that RGRN-305 would compete against on convenience and label breadth.

TypeDirect peer
Description

Clinical-stage biotech with lead asset sonelokinab in hidradenitis suppurativa. Closely comparable to Regranion in stage (clinical), therapeutic focus on HS, single-asset profile, and small-cap biotech characteristics.

TypeBroad incumbent
Description

Markets Cosentyx (secukinumab), a leading IL-17 inhibitor for psoriasis and HS. Directly competes with Regranion's target indications and represents a major class competitor.

TypeBroad incumbent
Description

Develops and commercializes Bimzelx for psoriasis, psoriatic arthritis, and HS. Comparable as a direct therapeutic competitor targeting Regranion's lead indications.

TypeDirect peer
Description

Late clinical-stage dermatology company with approved and pipeline products in inflammatory skin diseases including psoriasis. Comparable in clinical-stage dermatology specialty focus and small-cap biotech profile to Regranion.

TypeBroad incumbent
Description

Markets Stelara and Tremfya for psoriasis and HS. Comparable as a leading IL-12/23 and IL-23 inhibitor in Regranion's target patient populations.

TypeBroad incumbent
Description

Markets Otezla (apremilast), an oral PDE4 inhibitor approved for psoriasis and other indications. Directly comparable as an oral systemic competitor to RGRN-305 in plaque psoriasis.

TypeBroad incumbent
Description

Global biopharmaceutical leader with Humira, Skyrizi, and Rinvoq spanning psoriasis and HS. Sets the commercial, pricing, and access bar that any new autoimmune skin entrant like Regranion must compete against.

TypeBroad incumbent
Description

Markets Taltz (ixekizumab) for psoriasis and psoriatic arthritis. Comparable as a major IL-17 competitor in Regranion's target plaque psoriasis market.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Regranion

Dermatology Pharmaceuticalsregranion.com

What Regranion does

Regranion, LLC is a clinical-stage biopharmaceutical company developing RGRN-305, an orally delivered small molecule inhibitor of heat shock protein 90 (HSP90), for the treatment of autoimmune skin diseases. Founded in 2009 and headquartered in Mount Pleasant, United States, the company operates with a small team of 1-10 employees and is pre-revenue. Its lead asset targets hyperinflammation in moderate to severe plaque psoriasis and hidradenitis suppurativa (HS), with a mechanism of action designed to downregulate multiple inflammatory mediators simultaneously rather than inhibiting a single cytokine or chemokine.

RGRN-305 has demonstrated clinical safety and efficacy in both psoriasis and hidradenitis suppurativa trials, with no specific organ toxicity concerns and no consistent changes in hematology or biochemistry parameters reported in the available data. The product's pharmacological differentiation rests on broad-spectrum anti-inflammatory activity through HSP90 inhibition, an approach positioned by the company as addressing unmet clinical need in moderate to severe disease where single-target biologics have limitations.

The business model is a traditional pharmaceutical product sales model contingent on regulatory approval. The anticipated go-to-market is enterprise field sales targeting dermatologists, hospital systems, and specialty pharmacy channels, with distribution expected to flow through standard pharmaceutical wholesalers and specialty pharmacy networks upon commercialization. No pricing, partnerships, or capital structure details are disclosed in the source material.

Regranion firmographics

Firmographics
Name
Regranion
Legal name
Regranion, LLC
Website
https://regranion.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Regranion industry classification

Industry
Product category
Dermatology Pharmaceuticals
akta.pro industry
PRIMARYHLAKACAH
Acne & Rosacea Specialty Care

Keywords

  • Autoimmune skin diseases
  • HSP90 inhibitor
  • Clinical-stage biopharmaceutical
  • Small molecule therapeutics
  • Anti-inflammatory drugs

Where Regranion is headquartered

Location

Headquarters

HQ city
Mount Pleasant
HQ country
United States
HQ region
North America

Markets served

Regranion business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biopharmaceutical company. Revenue expected upon regulatory approval and commercialization of RGRN-305 for psoriasis and hidradenitis suppurativa. Revenue model would be traditional pharmaceutical product sales through prescription channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Regranion product offering

Product offering

Core offering

Regranion is a clinical-stage biopharmaceutical company developing RGRN-305, an orally delivered small molecule inhibitor of heat shock protein 90 (HSP90) for the treatment of autoimmune skin diseases. The lead product targets hyperinflammation in moderate to severe plaque psoriasis and hidradenitis suppurativa through broad-spectrum anti-inflammatory activity, modulating multiple inflammatory mediators simultaneously rather than individual cytokines or chemokines.

Product overview

Regranion is a clinical-stage biopharmaceutical company with a single lead product, RGRN-305. RGRN-305 is an orally delivered potent small molecule HSP90 inhibitor that functions as a broad-spectrum anti-inflammatory molecule, targeting multiple inflammatory mediators of autoimmune skin diseases rather than individual cytokines or chemokines. The product is in clinical development for hidradenitis suppurativa and plaque psoriasis, demonstrating clinical safety and efficacy without specific organ toxicity concerns.

Differentiator

Problem solved

Functional benefit

Products and services

  • RGRN-305

Quantifiable outcome

  • No specific organ toxicity concerns and no consistent changes in hematology or biochemistry parameters in clinical trials
  • +1 more outcomes

Companies that use Regranion

Customer profile

Segments1 record

Ideal customer profiles1 record

Regranion technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Regranion partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Regranion competitors and assessment

Company assessment

Broad incumbents

  • Galderma: Dermatology-focused specialty pharma with products spanning acne, rosacea, and other inflammatory skin conditions. Indirectly comparable as a dermatology-specialized competitor with overlapping physician channels.
  • Bristol-Myers Squibb: Markets Sotyktu (deucravacitinib), a first-in-class oral TYK2 inhibitor for psoriasis. Highly relevant comparator as the leading oral systemic that RGRN-305 would compete against on convenience and label breadth.
  • Novartis: Markets Cosentyx (secukinumab), a leading IL-17 inhibitor for psoriasis and HS. Directly competes with Regranion's target indications and represents a major class competitor.
  • UCB: Develops and commercializes Bimzelx for psoriasis, psoriatic arthritis, and HS. Comparable as a direct therapeutic competitor targeting Regranion's lead indications.
  • Johnson & Johnson (Janssen): Markets Stelara and Tremfya for psoriasis and HS. Comparable as a leading IL-12/23 and IL-23 inhibitor in Regranion's target patient populations.
  • Amgen: Markets Otezla (apremilast), an oral PDE4 inhibitor approved for psoriasis and other indications. Directly comparable as an oral systemic competitor to RGRN-305 in plaque psoriasis.
  • AbbVie: Global biopharmaceutical leader with Humira, Skyrizi, and Rinvoq spanning psoriasis and HS. Sets the commercial, pricing, and access bar that any new autoimmune skin entrant like Regranion must compete against.
  • Eli Lilly: Markets Taltz (ixekizumab) for psoriasis and psoriatic arthritis. Comparable as a major IL-17 competitor in Regranion's target plaque psoriasis market.

Direct peers

  • Moonlake Immunotherapeutics: Clinical-stage biotech with lead asset sonelokinab in hidradenitis suppurativa. Closely comparable to Regranion in stage (clinical), therapeutic focus on HS, single-asset profile, and small-cap biotech characteristics.
  • Arcutis Biotherapeutics: Late clinical-stage dermatology company with approved and pipeline products in inflammatory skin diseases including psoriasis. Comparable in clinical-stage dermatology specialty focus and small-cap biotech profile to Regranion.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Regranion social profiles

Digital presence

Regranion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Regranion leadership team

Management profile

Number of profiles

Profiles1 record

Regranion funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Regranion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regranion

What does Regranion do?

Regranion is a clinical-stage biopharmaceutical company developing RGRN-305, an orally delivered small molecule inhibitor of heat shock protein 90 (HSP90) for the treatment of autoimmune skin diseases. The lead product targets hyperinflammation in moderate to severe plaque psoriasis and hidradenitis suppurativa through broad-spectrum anti-inflammatory activity, modulating multiple inflammatory mediators simultaneously rather than individual cytokines or chemokines.

Is Regranion a public or private company?

Regranion is a private company. It is classified as unknown and is currently operating.

When was Regranion founded?

Regranion was founded in 2009. It employs 1 to 10 people.

Where is Regranion based?

Regranion is headquartered in Mount Pleasant, United States, in the North America region.

How does Regranion make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Regranion's main competitors?

Broad incumbents on record are Galderma, Bristol-Myers Squibb, Novartis, UCB, Johnson & Johnson (Janssen), Amgen, AbbVie and Eli Lilly. Direct peers are Moonlake Immunotherapeutics and Arcutis Biotherapeutics.

Does Regranion have an API?

No public API is recorded for Regranion.

What industry is Regranion in?

Regranion's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAKACAH, Acne & Rosacea Specialty Care.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales